Complicated Urinary Tract Infection Including Acute Pyelonephritis
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Evopoint BiosciencesChina - Beijing
1 program1
Combination of Imipenem/Cilastatin and XNW4107Phase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Evopoint BiosciencesCombination of Imipenem/Cilastatin and XNW4107
Clinical Trials (1)
Total enrollment: 780 patients across 1 trials
Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
Start: Mar 2023Est. completion: Dec 2025780 patients
Phase 3Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space